Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden.
Int J Pediatr Otorhinolaryngol. 2023 Aug;171:111632. doi: 10.1016/j.ijporl.2023.111632. Epub 2023 Jun 17.
Supraglottoplasty (SGP) for severe laryngomalacia (LM) in children with medical comorbidities has been associated with high risk of surgical failure and increased need of postoperative pediatric intensive care unit (PICU) intervention, but evidence for this is ambiguous. The objective was to evaluate surgical outcome and risk of need for PICU-intervention following SGP for severe LM in comorbid patients.
Retrospective observational study of 116 patients treated with SGP for severe LM between 2000 and 2021 at a tertial referral pediatric airway surgery center Karolinska University Hospital. Medical records were reviewed and patient data regarding surgical timing, type of SGP procedure, PICU-intervention, complications, and outcomes were recorded. Patients were defined as non-comorbid vs high-risk comorbid (HRC) based on a coexisting comorbidity for risk of surgical failure and postoperative PICU-intervention. Surgical failure was defined as need of revision surgery, tracheostomy or assisted ventilation (continuous positive airway pressure and bilevel positive airway pressure). PICU intervention was defined as need of postoperative assisted ventilation or intubation. Statistical comparisons were performed with outcome of SGP on children with LM and no comorbidities.
41/116 patients included had a HRC associated with an increased risk of PICU-intervention and surgical failure. 75/116 patients were defined as non-comorbid. The overall surgical success in the study population was 89.7% (104/116), 94.7% in the non HRC group vs 80.5% in the HRC-group. 5/41 HRC patients and 1/75 non-comorbid patients needed SGP revision in which 5/6 was successful. There was no significantly increased need for postoperative PICU intervention in HRC patients.
SGP for severe LM patients with high-risk comorbidities performed in a tertiary setting had an overall good result and low risk of PICU-intervention. Revision SGP was more common in HRC patients but had a good outcome. Multidisciplinary experience in perioperative care of comorbid patients may be of key importance for outcome and children with high-risk comorbidities should thus not be withheld the possible benefit of SGP without assessment at a tertiary pediatric airway center.
患有合并症的儿童行杓状软骨成形术(SGP)治疗重度喉软化症(LM)与手术失败风险高和术后需要更多儿科重症监护病房(PICU)干预相关,但这方面的证据尚不清楚。本研究旨在评估合并症患儿行 SGP 治疗重度 LM 的手术结果和 PICU 干预需求的风险。
这是一项在 2000 年至 2021 年期间于三级转诊儿科气道外科中心 Karolinska 大学医院接受 SGP 治疗重度 LM 的 116 例患者的回顾性观察性研究。回顾病历并记录手术时机、SGP 手术类型、PICU 干预、并发症和结局等患者数据。根据手术失败和术后 PICU 干预的风险,将患者定义为无合并症和高危合并症(HRC)。手术失败定义为需要再次手术、气管造口术或辅助通气(持续气道正压通气和双水平气道正压通气)。PICU 干预定义为需要术后辅助通气或插管。将 SGP 治疗合并症和无合并症的儿童的结局进行统计学比较。
116 例患者中,41 例存在与 PICU 干预和手术失败风险增加相关的 HRC。116 例患者中,75 例为非合并症。研究人群的总体手术成功率为 89.7%(104/116),非 HRC 组为 94.7%,HRC 组为 80.5%。41 例 HRC 患者中有 5 例和 75 例非合并症患者中有 1 例需要 SGP 修正,其中 6 例中的 5 例成功。HRC 患者术后 PICU 干预的需求无显著增加。
在三级医疗中心,对患有高危合并症的重度 LM 患者行 SGP 治疗具有良好的总体效果,且 PICU 干预的风险较低。HRC 患者中 SGP 修正更为常见,但结局良好。对合并症患者围手术期管理的多学科经验可能对结局至关重要,因此,不应在未在三级儿科气道中心进行评估的情况下,让患有高危合并症的儿童失去 SGP 治疗的可能获益。